Eculizumab interruption in atypical hemolytic uremic syndrome due to shortage: analysis of a Brazilian cohort.
Miguel Ernandes NetoLucas de Moraes SolerHalita Vieira Gallindo VasconcelosHong Si NgaAriane Moyses BravinJulio Cesar Andriotti BorgesRodrigo Costa GonçalvesRodrigo Brum Von KriigerRaquel Martins QuininoViviane Brandão Bandeira de Mello SantanaMaria Izabel de HolandaMaria Helena VaisbichAlice Pignaton NaseriGianna Mastroianni KirsztajnLilian Monteiro Pereira PalmaLuís Gustavo Modelli AndradePublished in: Journal of nephrology (2021)
In this study, the cumulative incidence of aHUS relapse at 397 days was 58% after eculizumab interruption. The presence of complement variant does not seem to be associated with a higher relapse rate. The eculizumab interruption was deemed not safe, considering that the rate of relapse was high.
Keyphrases